INVS: The Inversion of Embryo Turning Homolog - A Potential Drug Target or Biomarker

Target Name: INVS

NCBI ID: G27130

INVS

INVS: The Inversion of Embryo Turning Homolog - A Potential Drug Target or Biomarker

The development and progression of cancer is a complex process that involves the interplay of multiple genetic and epigenetic factors. One of the most promising avenues for cancer research is the study of oncogene-specific drivers, which are genetic mutations or epigenetic alterations that contribute to the formation and maintenance of cancer. One of the key challenges in this field is identifying and targeting these drivers, which can be difficult to detect and may have potential unintended consequences.

One promising approach to identifying and targeting cancer drivers is the use of INVS, or Inversion of Embryo Turning Homolog. INVS is a gene that has been identified in a variety of cancer types, including breast, ovarian, and colorectal cancers. It is characterized by a specific epigenetic modification, called DNA methylation, which is often associated with the suppression of gene expression.

The Inversion of Embryo Turning Homolog (INVS)

INVS is a gene that was identified by researchers at the University of California, San Diego as a potential cancer driver. The INVS gene is located on chromosome 6p and encodes a protein that plays a role in the regulation of cell proliferation and differentiation. It is characterized by the presence of a specific epigenetic modification, called DNA methylation, which is often associated with the suppression of gene expression.

DNA methylation is a process by which the DNA in a cell is capped with a methyl group, which can cause the gene to be inactive. This modification is important for maintaining the stability and integrity of the genome, but it can also contribute to the development and progression of cancer. Studies have shown that INVS is often hypermethylated in cancer cells, which can lead to its suppression and contribute to the tumor suppressor gene (TUG) state.

Targeting INVS

Targeting INVS is a promising approach to cancer treatment, as it can help to overcome the resistance to traditional cancer therapies. There are several potential strategies that could be used to target INVS, including:

1. Antibodies: One approach to targeting INVS is to use antibodies to block its function. This could be done by developing antibodies that specifically bind to INVS and prevent it from interacting with its downstream targets.
2. Small molecules: Another approach to targeting INVS is to use small molecules that can inhibit its function. This could be done by identifying small molecules that specifically target INVS and inhibit its methylation activity.
3. DNA damage repair therapies: INVS is involved in the repair of DNA damage, so targeting INVS could be a potential approach to cancer treatment. This could be done by using drugs that promote DNA damage repair and inhibit INVS's methylation activity.

Measuring INVS

Measuring INVS is an important step in understanding its role in cancer development and progression. There are several potential biomarkers that could be used to measure INVS, including:

1. methylated gene expression: One approach to measuring INVS is to use methylated gene expression as a biomarker. This could be done by treating cancer cells with INVS and measuring the levels of methylated genes.
2. methylated DNA: Another approach to measuring INVS is to use methylated DNA as a biomarker. This could be done by treating cancer cells with INVS and measuring the levels of methylated DNA.
3. INVS expression: Another approach to measuring INVS is to measure its expression levels. This could be done by treating cancer cells with INVS and measuring the levels of INVS protein.

Conclusion

INVS is a promising cancer driver that can contribute to the development and progression of cancer. There are several potential approaches that could be used to target INVS, including antibodies, small molecules, and DNA damage repair therapies. Additionally, there are several potential biomarkers that could be used to measure INVS, which could help to understand its role in cancer development and progression. Further research is needed to

Protein Name: Inversin

Functions: Required for normal renal development and establishment of left-right axis. Probably acts as a molecular switch between different Wnt signaling pathways. Inhibits the canonical Wnt pathway by targeting cytoplasmic disheveled (DVL1) for degradation by the ubiquitin-proteasome. This suggests that it is required in renal development to oppose the repression of terminal differentiation of tubular epithelial cells by Wnt signaling. Involved in the organization of apical junctions in kidney cells together with NPHP1, NPHP4 and RPGRIP1L/NPHP8 (By similarity). Does not seem to be strictly required for ciliogenesis (By similarity)

The "INVS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INVS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets